Journal of Cardiovascular Pharmacology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Adrenergic Receptor Regulation of Mitochondrial Function in Cardiomyocytes: Erratum
No abstract available (Source: Journal of Cardiovascular Pharmacology)
Source: Journal of Cardiovascular Pharmacology - November 1, 2022 Category: Cardiology Tags: Erratum Source Type: research

Milrinone Versus Sildenafil in Treatment of Neonatal Persistent Pulmonary Hypertension: A Randomized Control Trial
This study aimed to assess the efficacy of milrinone versus sildenafil as available alternative therapeutics in treating PPHN. Forty neonates (>34 weeks) admitted to neonatal intensive care units with evidence of PPHN were randomly allocated to receive either oral sildenafil (0.5–2 mg/kg/6 hours) or intravenous milrinone (0.25–0.75 mic/kg/min). Primary outcomes included improvements in systolic pulmonary artery pressure and oxygen saturation index (OSI) at 24 and 48 hours after treatment. Secondary outcomes included the duration of hospitalization and mechanical ventilation. The ClinicalTrials identifier is NCT04391478...
Source: Journal of Cardiovascular Pharmacology - November 1, 2022 Category: Cardiology Tags: Clinical Trials Source Type: research

Stabilizing Cardiac Ryanodine Receptor With Dantrolene Treatment Prevents Binge Alcohol–Enhanced Atrial Fibrillation in Rats
In this study, we investigated whether stabilizing RyR2 with dantrolene treatment can prevent alcohol-enhanced AF in rats. A binge drinking rat model was established with alcohol (2g/kg, IP) delivered once every other day for 4 times. The study consisted of following 3 groups: control group (n = 9), binge alcohol group (n = 10), and binge alcohol + dantrolene (A+D) group (dantrolene, 10 mg/kg, IP before each alcohol injection, n = 9). Echocardiography, left ventricular hemodynamics, in vivo atrial electrophysiology and AF inducibility test, RyR2 phosphorylation level, and blood norepinephrine level were studied 24 hours af...
Source: Journal of Cardiovascular Pharmacology - November 1, 2022 Category: Cardiology Tags: Original Article Source Type: research

Atorvastatin Ameliorates Doxorubicin-Induced Cardiomyopathy by Regulating the Autophagy–Lysosome Pathway and Its Upstream Regulatory Factor Transcription Factor EB
This study explored the role of TFEB in DIC and the possible mechanism of ATO in improving DIC and used statins to prevent and treat DIC; various dilated cardiomyopathy and heart failure diseases provide more experimental evidence. All relevant data are within the article and its supporting information files. (Source: Journal of Cardiovascular Pharmacology)
Source: Journal of Cardiovascular Pharmacology - November 1, 2022 Category: Cardiology Tags: Original Article Source Type: research

The Functional Effects of Visfatin on Human Left Internal Mammary Artery
In this study, visfatin caused endothelium-dependent relaxations mediated by nitric oxide–cyclic guanosine monophosphate pathway and nicotinamide phosphoribosyltransferase activity. Furthermore, visfatin-induced decreases in relaxation responses were also related to endothelium-derived nitric oxide. (Source: Journal of Cardiovascular Pharmacology)
Source: Journal of Cardiovascular Pharmacology - November 1, 2022 Category: Cardiology Tags: Original Article Source Type: research

Renal Safety and Renin–Angiotensin–Aldosterone System Inhibitors in Patients With Contrast Media Exposure: A Multicenter Randomized Controlled Study
Abstract: There is no clear consensus on the safety of renin–angiotensin–aldosterone system inhibitors in patients with contrast media exposure. We aimed to assess the safety of renin–angiotensin–aldosterone system inhibitors in patients exposed to contrast media at 1-year follow-up. Patients treated with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) were recruited and randomly divided into 2 groups (1:1 ratio): with ACEI/ARB group (ACEI/ARB continued throughout the study period) and without ACEI/ARB group (ACEI/ARB stopped 24 hours before and continued 48 hours after the proce...
Source: Journal of Cardiovascular Pharmacology - November 1, 2022 Category: Cardiology Tags: Original Article Source Type: research

LincRNA RMRP Regulates Phenylephrine-induced Cardiomyocyte Hypertrophy by Means of Targeting miR-1
In this study, the expression of linc-RMRP and its correlation with cardiac hypertrophy were analyzed in cardiac tissues of patients with HCM. Real-time qPCR and western blotting measured the expressions of lincf-RMRP, miR-1, and hypertrophic marker genes. RNA pulldown and luciferase reporter gene assays were performed to validate the combination between linc-RMRP and miR-1. We confirmed that Linc-RMRP was upregulated in both cardiac hypertrophy tissues and phenylephrine (PE)-induced CH cells, and the cells presented hypertrophic features, enlarged cell surface area and volume, elevated total protein contents, and increase...
Source: Journal of Cardiovascular Pharmacology - November 1, 2022 Category: Cardiology Tags: Original Article Source Type: research

Efficacy and Safety of Shortened Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials
In conclusion, this study showed that ≤3-month DAPT may be a valid option for most patients after percutaneous coronary intervention. Because reductions in major adverse cardiovascular event, all-cause mortality, and cardiovascular mortality were not seen in patients with HBR, this also highlights the need for specific studies in these patients about optimal duration of antiplatelet therapy. (Source: Journal of Cardiovascular Pharmacology)
Source: Journal of Cardiovascular Pharmacology - November 1, 2022 Category: Cardiology Tags: Original Article Source Type: research

Ethoxyquin is a Competent Radical-Trapping Antioxidant for Preventing Ferroptosis in Doxorubicin Cardiotoxicity
Doxorubicin (DOX) is an effective anti-cancer agent for various malignancies. Nevertheless, it has a side effect of cardiotoxicity, referred to as doxorubicin-induced cardiomyopathy (DIC), that is associated with a poorer prognosis. This cardiotoxicity limits the clinical use of DOX as a therapeutic agent for malignancies. Recently, ferroptosis, a form of regulated cell death induced by the accumulation of lipid peroxides, has been recognized as a major pathophysiology of DIC. Ethoxyquin is a lipophilic antioxidant widely used for food preservation and thus may be a potential therapeutic drug for preventing DIC. However, t...
Source: Journal of Cardiovascular Pharmacology - November 1, 2022 Category: Cardiology Tags: Original Article Source Type: research

Molecular Determinants for the High-Affinity Blockade of Human Ether-à-go-go-Related Gene K+ Channel by Tolterodine
In conclusion, tolterodine is an open-state blocker of hERG K+ channel with nanomolar potency. Y652 and F656, 2 aromatic residues on the inner S6 helix, are responsible for the high-affinity binding of tolterodine to hERG channel. (Source: Journal of Cardiovascular Pharmacology)
Source: Journal of Cardiovascular Pharmacology - November 1, 2022 Category: Cardiology Tags: Original Article Source Type: research

Safety, Tolerability, and Effects of a Single Subcutaneous Administration of SP16 – a SERPIN-like, Small Peptide Agonist of the Low-Density Lipoprotein–like Receptor 1– on the Acute Inflammatory Response in Patients With ST-Segment Elevation Myocardial Infarction
Conclusion: A single subcutaneous administration of SP16, a synthetic targeted LRP1 agonist, was safe and well-tolerated in patients with STEMI. A trend toward reduction in the inflammatory response and infarct size with SP16 was noted; however, the sample size for this study was not based on formal statistical criteria. More extensive studies are planned to determine the clinical efficacy of SP16 in STEMI. NCT: NCT04225533. (Source: Journal of Cardiovascular Pharmacology)
Source: Journal of Cardiovascular Pharmacology - November 1, 2022 Category: Cardiology Tags: Drugs in the Pipeline: Original Article Source Type: research

Contrast-induced Acute Kidney Injury in Diabetic Patients and SGLT-2 Inhibitors: A Preventive Opportunity or Promoting Element?
Abstract: Contrast-induced acute kidney injury (CI-AKI) is a serious complication in patients undergoing diagnostic or therapeutic procedures that require contrast use and negatively affects the long-term outcomes. Patients with type 2 diabetes mellitus (DM), particularly those who have already developed diabetic nephropathy (DN), are more susceptible to contrast-induced renal damage. Indeed, contrast media amplify some pathological molecular and cellular pathways already in place in the DN setting. In recent years, sodium–glucose cotransporter-2 inhibitors (SGLT2i) have triggered a paradigm shift in managing patient...
Source: Journal of Cardiovascular Pharmacology - November 1, 2022 Category: Cardiology Tags: Review Article Source Type: research

Advances in Nanoformulated Polyphenols for Protection Against Cardiovascular Diseases
Abstract: In the past decade, a plethora of research has revealed numerous biological effects of polyphenols, most significantly anticancer and antimicrobial. These versatile, naturally occurring compounds have attracted growing interest among researchers owing to their crucial role in modifying disease progression associated with almost all the body's vital systems, including cardiovascular, neurological, and gastrointestinal systems. However, poor water solubility and rapid metabolism result in low bioavailability, which is a critical limitation to their clinical use. Nanotechnology is one promising approach that has...
Source: Journal of Cardiovascular Pharmacology - November 1, 2022 Category: Cardiology Tags: Review Article Source Type: research

Evaluating the Utility of Colchicine in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis
Abstract: Colchicine has demonstrated promising effects in inhibiting local and systemic inflammation during acute coronary syndrome (ACS). However, the efficacy of colchicine in ACS is controversial. We performed a meta-analysis to assess the utility of colchicine in ACS by systematically searching randomized controlled trials. Recurrent myocardial infarction, coronary revascularization, and stroke were included as efficacy endpoint parameters whereas safety endpoints chosen were all-cause mortality, cardiovascular mortality, infectious events, and gastrointestinal (GI) adverse events. Nine identified studies were inc...
Source: Journal of Cardiovascular Pharmacology - November 1, 2022 Category: Cardiology Tags: Review Article Source Type: research

Holiday Heart Syndrome, Atrial Fibrillation, and RyR2 Antagonist
No abstract available (Source: Journal of Cardiovascular Pharmacology)
Source: Journal of Cardiovascular Pharmacology - November 1, 2022 Category: Cardiology Tags: Commentary Source Type: research